HMN 2025: How Studies handle muscle loss brought on by GLP-1 medicine

GLP-1 medicine like Ozempic and Zepbound are nice at selling weight reduction, however additionally they trigger of us to lose muscle together with fats.

Experts are actually turning their consideration towards serving to GLP-1 sufferers keep muscle whereas dropping fats, in accordance with a pair of recent research introduced on the American Diabetes Association’s annual meeting in Chicago.

An experimental muscle-preserving drug known as bimagrumab helped folks taking semaglutide (Ozempic/Wegovy) hold their muscle whereas reducing weight, in accordance with scientific trial outcomes.

In a separate study introduced Sunday, researchers unveiled a possible check for monitoring weight reduction amongst GLP-1 sufferers.

“As we enter a brand new period of weight problems remedies, it is vital to focus not simply on the quantity of weight misplaced, however on preserving muscle mass and gaining the well being advantages that outcome from treating weight problems,” Dr. Samar Hafida, vice chairman of the Obesity Association—a division of the ADA—mentioned in a information launch.

The variety of Americans taking GLP-1 medicine has elevated almost six-fold over bygone days 5 years, the ADA mentioned in background notes.

Unfortunately, as a lot as 40% of the burden dropped on these medicine comes from lack of muscle mass relatively than fats, the ADA says.

This muscle loss can have dramatic results on an individual’s well being. Lean muscle mass stabilizes blood sugar, boosts immunity, protects bones and joints, and revs up metabolism, in accordance with Northwell Health.

To attempt to forestall that loss, researchers mixed bimagrumab with semaglutide in a scientific trial involving greater than 500 folks.

Bimagrumab is a lab-made antibody that blocks a protein known as activin sort II. This protein helps {control} how a lot muscle an individual has. By blocking it, the drug helps the physique construct extra muscle.

The drug was initially developed within the 2010s as a method of combating muscle losing ailments. Pharmaceutical agency Eli Lilly and Company—which makes Zepbound—is creating bimagrumab as a method of treating weight problems.

Patients assigned bimagrumab within the scientific trial acquired IV infusions of the drug at weeks 4, 16, 28 and 40.

The mixture of bimagrumab and semaglutide brought on almost 93% of individuals’s common weight reduction to come back from fats mass alone, outcomes present.

By comparability, weight reduction from fats alone amounted to simply 72% for these taking simply semaglutide, researchers discovered.

People additionally misplaced extra physique weight on the mix—a 22% lower in weight in contrast with 11% for bimagrumab alone and 16% for semaglutide alone.

Researchers famous that in individuals who solely took bimagrumab, 100% of weight reduction got here from fats melting away. These sufferers additionally had a greater than 2% improve of their lean muscle mass.

“These insights point out that isn’t solely attainable to attain substantial fats loss, but additionally to protect, and even improve, lean mass within the course of,” lead researcher Dr. Steven Heymsfield, a professor at Pennington Biomedical Research Center in Baton Rouge, La., mentioned in a information launch.

Researchers are actually testing bimagrumab together with Zepbound to additional consider the combo method.

In the second study, researchers found out a technique to monitor muscle loss that happens throughout GLP-1 therapy.

The staff developed a biosensor to trace phenylalanine, an amino acid produced when muscle breaks down or through the digestion of protein.

Phenylalanine ranges in wholesome persons are 100 uM/L or larger following a high-protein meal, researchers mentioned.

They designed their biosensor to detect phenylalanine ranges as much as 1500 uM/L, which could point out muscle loss.

“GLP-1 medicines have remodeled the therapy of diabetes and weight problems, however they will additionally improve the chance of muscle loss,” lead researcher Rebecca Gottlieb, vice chairman of Advanced Sensor Technologies at Biolinq, mentioned in a information launch.

“While sufferers are suggested to eat extra protein to protect muscle, it is usually troublesome to know in the event that they’re getting sufficient,” Gottlieb mentioned. “That is why options to bridge this hole by offering real-time suggestions are extra vital than ever—particularly for these on GLP-1 therapies, older adults, or anybody managing sarcopenia.”

Researchers subsequent plan to conduct scientific trials to guage the sensor’s real-world efficiency.